{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:40:41Z","timestamp":1791636041309,"version":"4.3.4"},"reference-count":60,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung (BMBF, Germany)","doi-asserted-by":"publisher","award":["03LW0348K"],"award-info":[{"award-number":["03LW0348K"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung (BMBF, Germany)","doi-asserted-by":"publisher","award":["03LW0348K"],"award-info":[{"award-number":["03LW0348K"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Ministerium f\u00fcr Wirtschaft, Forschung und Kultur (MWFK, state of Brandenburg, Germany)","doi-asserted-by":"publisher","award":["03LW0348K"],"award-info":[{"award-number":["03LW0348K"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Ministerium f\u00fcr Wirtschaft, Forschung und Kultur (MWFK, state of Brandenburg, Germany)","doi-asserted-by":"publisher","award":["03LW0348K"],"award-info":[{"award-number":["03LW0348K"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The metabolism of drugs and foreign substances in humans typically involves multiple enzymatic steps, particularly in phase-1 biotransformation in the liver, where various cytochrome P450 monooxygenases (CYPs) play crucial roles. This complexity can lead to a wide range of metabolites. Understanding the contributions of individual CYPs and their interactions within these intricate enzyme cascades can be challenging. We recently developed an in vitro biotransformation platform employing various Chinese Hamster Ovarian (CHO) cell clones. These clones express human cytochrome P450 oxidoreductase (CPR), and each is defined by a specific human CYP enzyme expression, thus exhibiting no detectable endogenous CYP enzyme activity (mono-CYP CHO platform). In this study, we investigated whether the mono-CYP CHO platform is a suitable tool for modeling complex drug metabolization reactions in vitro. Tamoxifen (TAM) was selected as a model substance due to its role as a prodrug widely used in breast cancer therapy, where its main active metabolite, endoxifen, arises from a two-step metabolism primarily involving the CYP system. Specifically, the combined activity of CYP3A4 and CYP2D6 is believed to be essential for efficient endoxifen production. However, the physiological metabolization pathway of TAM is more complex and interconnected, and the reasons for TAM\u2019s therapeutic success and variability among patients are not yet fully understood. Analogous to our recently introduced mono-CYP3A4 CHO cells, we generated a CHO cell line expressing human CPR and CYP2D6, including analysis of CYP2D6 expression and specific activity. Comparative studies on the metabolization of TAM were performed with both mono-CYP CHO models individually and in co-culture with intact cells as well as with isolated microsomes. Supernatants were analyzed by HPLC to calculate individual CYP activity for each metabolite. All the picked mono-CYP2D6 clones expressed similar CYP2D6 protein amounts but showed different enzyme activities. Mono-CYP2D6 clone 18 was selected as the most suitable for TAM metabolization based on microsomal activity assays. TAM conversion with mono-CYP2D6 and -3A4 clones, as well as the combination of both, resulted in the formation of the expected main metabolites. Mono-CYP2D6 cells and microsomes produced the highest detected amounts of 4-hydroxytamoxifen and endoxifen, along with N-desmethyltamoxifen and small amounts of N,N-didesmethyltamoxifen. N-desmethyltamoxifen was the only TAM metabolite detected in notable quantities in mono-CYP3A4, while 4-hydroxytamoxifen and endoxifen were present only in trace amounts. In CYP2D6\/3A4 co-culture and equal mixtures of both CYP microsomes, all metabolites were detected at concentrations around 50% of those in individual clones, indicating no significant synergistic effects. In conclusion, our mono-CYP CHO model confirmed the essential role of CYP2D6 in synthesizing the active TAM metabolite endoxifen and indicated that CYP2D6 is also involved in producing the by-metabolite N,N-didesmethyltamoxifen. The differences in metabolite spectra between the two mono-CYP models highlight the CYP specificity and sensitivity of our in vitro system.<\/jats:p>","DOI":"10.3390\/ijms26093992","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T10:40:48Z","timestamp":1745404848000},"page":"3992","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mono-CYP CHO Model: A Recombinant Chinese Hamster Ovary Cell Platform for Investigating CYP-Specific Tamoxifen Metabolism"],"prefix":"10.3390","volume":"26","author":[{"given":"Christian","family":"Schulz","sequence":"first","affiliation":[{"name":"Fraunhofer Institute for Cell Therapy and Immunology, Branch Bioanalytics and Bioprocesses (IZI-BB), Site Lausitz (IZI-BB-L), 01968 Senftenberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7689-111X","authenticated-orcid":false,"given":"Sarah","family":"Stegen","sequence":"additional","affiliation":[{"name":"Fraunhofer Institute for Cell Therapy and Immunology, Branch Bioanalytics and Bioprocesses (IZI-BB), Site Lausitz (IZI-BB-L), 01968 Senftenberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Jung","sequence":"additional","affiliation":[{"name":"Institute of Biotechnology, Brandenburg University of Technology Cottbus-Senftenberg, 01968 Senftenberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Heiner","family":"K\u00fcpper","sequence":"additional","affiliation":[{"name":"Institute of Biotechnology, Brandenburg University of Technology Cottbus-Senftenberg, 01968 Senftenberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1021\/tx500444e","article-title":"Survey of human oxidoreductases and cytochrome P450 enzymes involved in the metabolism of xenobiotic and natural chemicals","volume":"28","author":"Rendic","year":"2015","journal-title":"Chem. Res. Toxicol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jinorgbio.2018.03.002","article-title":"Membrane-attached mammalian cytochromes P450: An overview of the membrane\u2019s effects on structure, drug binding, and interactions with redox partners","volume":"183","author":"Bazgier","year":"2018","journal-title":"J. Inorg. Biochem."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Hlengwa, N., Masilela, C., Mtambo, T.R., Sithole, S., Naidoo, S., Machaba, K.E., Shabalala, S.C., Ntamo, Y., Dludla, P.V., and Milase, R.N. (2023). In Vitro Hepatic Models to Assess Herb\u2013Drug Interactions: Approaches and Challenges. Pharmaceuticals, 16.","DOI":"10.3390\/ph16030409"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7.8.1","DOI":"10.1002\/cpph.9","article-title":"In vitro drug metabolism using liver microsomes","volume":"74","author":"Knights","year":"2016","journal-title":"Curr. Protoc. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Elbagoury, R.M., Shenouda, M.A., Elnakib, H.E., Wober, J., Abadi, A.H., and Ahmed, N.S. (2023). Design, synthesis, and metabolite identification of Tamoxifen esterase-activatable prodrugs. Bioorganic Chem., 131.","DOI":"10.1016\/j.bioorg.2022.106303"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3233\/JCB-179012","article-title":"Human hepatocyte systems for in vitro toxicology analysis","volume":"3","author":"Kammerer","year":"2018","journal-title":"J. Cell. Biotechnol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/00498250310001657568","article-title":"Phase I and II enzyme characterization of two sources of HepG2 cell lines","volume":"34","author":"Hewitt","year":"2004","journal-title":"Xenobiotica"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00204-016-1677-z","article-title":"Comparative analysis of 3D culture methods on human HepG2 cells","volume":"91","author":"Luckert","year":"2017","journal-title":"Arch. Toxicol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00204-017-2147-y","article-title":"The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes","volume":"92","author":"Thomas","year":"2018","journal-title":"Arch. Toxicol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1124\/jpet.104.065607","article-title":"Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6","volume":"310","author":"Desta","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/004982598238877","article-title":"In vitro assessment of human cytochrome P450","volume":"28","author":"Clarke","year":"1998","journal-title":"Xenobiotica"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kumondai, M., Hishinuma, E., Guti\u00e9rrez Rico, E.M., Ito, A., Nakanishi, Y., Saigusa, D., Hirasawa, N., and Hiratsuka, M. (2020). Heterologous expression of high-activity cytochrome P450 in mammalian cells. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-71035-5"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Satoh, D., Iwado, S., Abe, S., Kazuki, K., Wakuri, S., Oshimura, M., and Kazuki, Y. (2017). Establishment of a novel hepatocyte model that expresses four cytochrome P450 genes stably via mammalian-derived artificial chromosome for pharmacokinetics and toxicity studies. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0187072"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.toxlet.2019.11.006","article-title":"HepG2-1A2 C2 and C7: Lentivirus vector-mediated stable and functional overexpression of cytochrome P450 1A2 in human hepatoblastoma cells","volume":"319","author":"Steinbrecht","year":"2020","journal-title":"Toxicol. Lett."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/carcin\/23.11.1897","article-title":"Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA","volume":"23","author":"Boocock","year":"2002","journal-title":"Carcinogenesis"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/biot.201400438","article-title":"The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors","volume":"10","author":"Felberbaum","year":"2015","journal-title":"Biotechnol. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1006\/mben.2000.0147","article-title":"Bioreactor systems in drug metabolism: Synthesis of cytochrome P450-generated metabolites","volume":"2","author":"Rushmore","year":"2000","journal-title":"Metab. Eng."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5.4.1","DOI":"10.1002\/cpps.47","article-title":"Overview of the baculovirus expression system","volume":"91","author":"Chambers","year":"2018","journal-title":"Curr. Protoc. Protein Sci."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Schulz, C., Herzog, N., Kubick, S., Jung, F., and K\u00fcpper, J.-H. (2023). Stable Chinese hamster ovary suspension cell lines harboring recombinant human cytochrome P450 oxidoreductase and human cytochrome P450 monooxygenases as platform for in vitro biotransformation studies. Cells, 12.","DOI":"10.3390\/cells12172140"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1006\/abbi.1997.0405","article-title":"High levels of recombinant CYP3A4 expression in Chinese hamster ovary cells are modulated by coexpressed human P450 reductase and hemin supplementation","volume":"348","author":"Ding","year":"1997","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/aps.2013.132","article-title":"CYP3A4 overexpression enhances apoptosis induced by anticancer agent imidazoacridinone C-1311, but does not change the metabolism of C-1311 in CHO cells","volume":"35","author":"Augustin","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_22","first-page":"143","article-title":"V79 Chinese hamster cells genetically engineered for polymorphic cytochrome P450 2D6 and their predictive value for humans","volume":"20","author":"Krebsfaenger","year":"2003","journal-title":"ALTEX Altern. Anim. Exp."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Deeni, Y.Y., Ibbotson, S.H., Woods, J.A., Wolf, C.R., and Smith, G. (2013). Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0075494"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2174\/138920007782798207","article-title":"The conduct of drug metabolism studies considered good practice (II): In vitro experiments","volume":"8","author":"Jia","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2174\/1872312810666160223121836","article-title":"Efficiency in drug discovery: Liver S9 fraction assay as a screen for metabolic stability","volume":"10","author":"Richardson","year":"2016","journal-title":"Drug Metab. Lett."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M.S., and Catalano, A. (2023). Targeting breast cancer: An overlook on current strategies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043643"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet, 365, 1687\u20131717.","DOI":"10.1016\/S0140-6736(05)66544-0"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/sj.bjc.6600654","article-title":"Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer","volume":"87","author":"Murphy","year":"2002","journal-title":"Br. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/clpt.2011.27","article-title":"Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma","volume":"89","author":"Schroth","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/FPC.0b013e3283656bc1","article-title":"PharmGKB summary: Tamoxifen pathway, pharmacokinetics","volume":"23","author":"Klein","year":"2013","journal-title":"Pharmacogenetics Genom."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJM199811263392207","article-title":"Tamoxifen in the treatment of breast cancer","volume":"339","author":"Osborne","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0014-2964(75)90119-X","article-title":"Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor","volume":"11","author":"Jordan","year":"1975","journal-title":"Eur. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/256592a0","article-title":"Oestrogen-responsive human breast cancer in long term tissue culture","volume":"256","author":"Lippman","year":"1975","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/jcb.20690","article-title":"Cell cycle control in breast cancer cells","volume":"97","author":"Caldon","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1677\/joe.0.0750305","article-title":"A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity","volume":"75","author":"Jordan","year":"1977","journal-title":"J. Endocrinol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2133\/dmpk.DMPK-11-RV-084","article-title":"Pharmacogenomics of tamoxifen: Roles of drug metabolizing enzymes and transporters","volume":"27","author":"Kiyotani","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_37","first-page":"2304","article-title":"Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile","volume":"48","author":"Lien","year":"1988","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-007-9526-7","article-title":"TGF\u03b22 and T\u03b2RII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells","volume":"107","author":"Buck","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/B:BREA.0000025406.31193.e8","article-title":"Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen","volume":"85","author":"Johnson","year":"2004","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/jnci\/dji005","article-title":"CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment","volume":"97","author":"Jin","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1200\/JCO.2007.11.4850","article-title":"Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer","volume":"25","author":"Lim","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/jnci\/djg108","article-title":"Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine","volume":"95","author":"Stearns","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1158\/0008-5472.CAN-08-3933","article-title":"The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor \u03b1 for degradation in breast cancer cells","volume":"69","author":"Wu","year":"2009","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-011-1699-4","article-title":"The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents","volume":"133","author":"Lu","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_45","unstructured":"Giesbertz, P., Hanspers, K., Willighagen, E., Digles, D., Roudbari, Z., Slenter, D., and Weitz, E. (2025, April 17). Tamoxifen Metabolism. Available online: https:\/\/www.wikipathways.org\/instance\/WP691."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Helland, T., Alsomairy, S., Lin, C., S\u00f8iland, H., Mellgren, G., and Hertz, D.L. (2021). Generating a precision endoxifen prediction algorithm to advance personalized tamoxifen treatment in patients with breast cancer. J. Pers. Med., 11.","DOI":"10.3390\/jpm11030201"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/clpt.2011.32","article-title":"Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes","volume":"89","author":"Madlensky","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1124\/dmd.105.006551","article-title":"Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases","volume":"34","author":"Falany","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Gjerde, J., Geisler, J., Lundgren, S., Ekse, D., Varhaug, J.E., Mellgren, G., Steen, V.M., and Lien, E.A. (2010). Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-313"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/carcin\/15.4.589","article-title":"A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes","volume":"15","author":"Lim","year":"1994","journal-title":"Carcinogenesis"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1124\/dmd.30.8.869","article-title":"Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: Formation of the 4-hydroxy, 4\u2032-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen","volume":"30","author":"Crewe","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s00204-024-03710-9","article-title":"Formation of potentially toxic metabolites of drugs in reactions catalyzed by human drug-metabolizing enzymes","volume":"98","author":"Rendic","year":"2024","journal-title":"Arch. Toxicol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0090-9556(24)15305-6","article-title":"Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: Involvement of catechols in covalent binding to hepatic proteins","volume":"27","author":"Dehal","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1373\/clinchem.2008.121756","article-title":"Pharmacogenomics of tamoxifen therapy","volume":"55","author":"Brauch","year":"2009","journal-title":"Clin. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/sj.clpt.6100367","article-title":"Tamoxifen pharmacogenomics: The role of CYP2D6 as a predictor of drug response","volume":"83","author":"Goetz","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0378-5173(93)90323-8","article-title":"Adsorption of tamoxifen and 2-methyl derivatives under cell culture conditions","volume":"99","author":"Chamart","year":"1993","journal-title":"Int. J. Pharm."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jchromb.2017.09.041","article-title":"Different in vitro cellular responses to tamoxifen treatment in polydimethylsiloxane-based devices compared to normal cell culture","volume":"1068","author":"Wang","year":"2017","journal-title":"J. Chromatogr. B"},{"key":"ref_58","first-page":"2175","article-title":"Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment","volume":"49","author":"Lien","year":"1989","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/bjc.1991.457","article-title":"Reversible control of oestradiol-stimulated growth of MCF-7 tumours by tamoxifen in the athymic mouse","volume":"64","author":"Iino","year":"1991","journal-title":"Br. J. Cancer"},{"key":"ref_60","first-page":"6052","article-title":"Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: Possible involvement of flavin-containing monooxygenases in tamoxifen activation","volume":"51","author":"Mani","year":"1991","journal-title":"Cancer Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/9\/3992\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:20:11Z","timestamp":1760030411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/9\/3992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":60,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["ijms26093992"],"URL":"https:\/\/doi.org\/10.3390\/ijms26093992","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]}}}